Compare Stocks: AVXL, IMMX, FTH, and AVTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$15.72 +2.7%	$18.56	$10.70 ▼ $24.27	$885.43M	0.78	985,279 shs	1.90 million shs
AVXL Anavex Life Sciences	$2.34 -0.4%	$2.85	$2.26 ▼ $10.38	$228.96M	1.14	648,510 shs	937,021 shs
FTH Sensei Biotherapeutics	$29.05 -7.9%	$32.03	$7.45 ▼ $42.14	$863.07M	-0.28	400,476 shs	608,163 shs
IMMX Immix Biopharma	$11.70 -1.8%	$11.55	$1.98 ▼ $15.10	$917.85M	0.2	1.35 million shs	1.54 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	+2.75%	-5.81%	-20.36%	-13.45%	+35.52%
AVXL Anavex Life Sciences	-0.43%	-2.90%	-34.27%	-10.69%	-72.27%
FTH Sensei Biotherapeutics	-7.92%	-17.31%	-15.85%	+27.02%	+2,904,999,900.00%
IMMX Immix Biopharma	-1.85%	-8.02%	-19.14%	+17.23%	+470.73%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$15.72 +2.7%	$18.56	$10.70 ▼ $24.27	$885.43M	0.78	985,279 shs	1.90 million shs
AVXL Anavex Life Sciences	$2.34 -0.4%	$2.85	$2.26 ▼ $10.38	$228.96M	1.14	648,510 shs	937,021 shs
FTH Sensei Biotherapeutics	$29.05 -7.9%	$32.03	$7.45 ▼ $42.14	$863.07M	-0.28	400,476 shs	608,163 shs
IMMX Immix Biopharma	$11.70 -1.8%	$11.55	$1.98 ▼ $15.10	$917.85M	0.2	1.35 million shs	1.54 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	+2.75%	-5.81%	-20.36%	-13.45%	+35.52%
AVXL Anavex Life Sciences	-0.43%	-2.90%	-34.27%	-10.69%	-72.27%
FTH Sensei Biotherapeutics	-7.92%	-17.31%	-15.85%	+27.02%	+2,904,999,900.00%
IMMX Immix Biopharma	-1.85%	-8.02%	-19.14%	+17.23%	+470.73%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTX Avalo Therapeutics	2.85	Moderate Buy	$45.10	186.90% Upside
AVXL Anavex Life Sciences	2.40	Hold	$21.33	811.68% Upside
FTH Sensei Biotherapeutics	2.93	Moderate Buy	$56.25	93.63% Upside
IMMX Immix Biopharma	2.78	Moderate Buy	$22.86	95.36% Upside

Current Analyst Ratings Breakdown

Latest AVXL, IMMX, FTH, and AVTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	AVTX Avalo Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/16/2026	FTH Sensei Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$70.00
9/15/2026	FTH Sensei Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/15/2026	IMMX Immix Biopharma	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$15.00 ➝ $26.00
9/14/2026	FTH Sensei Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/9/2026	FTH Sensei Biotherapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
9/8/2026	AVXL Anavex Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/21/2026	FTH Sensei Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$56.00
8/14/2026	IMMX Immix Biopharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/11/2026	AVTX Avalo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	IMMX Immix Biopharma	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$20.00 ➝ $19.00

(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTX Avalo Therapeutics	$60K	14,051.06	N/A	N/A	$4.49 per share	3.50
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.10 per share	N/A
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	$14.74 per share	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	$1.77 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTX Avalo Therapeutics	-$78.26M	-$4.37	N/A	N/A	N/A	N/A	-58.03%	-48.22%	11/5/2026 (Estimated)
AVXL Anavex Life Sciences	-$46.38M	-$0.15	N/A	N/A	N/A	N/A	-11.43%	-10.72%	11/24/2026 (Estimated)
FTH Sensei Biotherapeutics	-$21.08M	-$141.65	N/A	N/A	N/A	N/A	-1,012.17%	-175.69%	N/A
IMMX Immix Biopharma	-$29.44M	-$0.88	N/A	N/A	N/A	N/A	-38.44%	-34.72%	11/6/2026 (Estimated)

Latest AVXL, IMMX, FTH, and AVTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/25/2026	Q2 2026	AVXL Anavex Life Sciences	-$0.08	$0.08	+$0.16	$0.08	N/A	N/A
8/7/2026	Q2 2026	IMMX Immix Biopharma	-$0.17	-$0.18	-$0.01	-$0.18	N/A	N/A
8/6/2026	Q2 2026	AVTX Avalo Therapeutics	-$0.5827	-$0.83	-$0.2473	-$0.83	N/A	N/A
8/4/2026	Q2 2026	FTH Sensei Biotherapeutics	-$5.0450	-$2.84	+$2.2050	-$0.62	N/A	N/A
7/30/2026	Q2 2026	AVXL Anavex Life Sciences	-$0.07	-$0.06	+$0.01	-$0.06	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTX Avalo Therapeutics	N/A	19.31	19.31
AVXL Anavex Life Sciences	N/A	15.62	15.62
FTH Sensei Biotherapeutics	N/A	19.69	19.69
IMMX Immix Biopharma	N/A	25.13	25.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTX Avalo Therapeutics	87.06%
AVXL Anavex Life Sciences	31.55%
FTH Sensei Biotherapeutics	10.50%
IMMX Immix Biopharma	11.26%

Insider Ownership

Company	Insider Ownership
AVTX Avalo Therapeutics	4.46%
AVXL Anavex Life Sciences	11.40%
FTH Sensei Biotherapeutics	7.00%
IMMX Immix Biopharma	30.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTX Avalo Therapeutics	33	53.63 million	51.24 million	Not Optionable
AVXL Anavex Life Sciences	34	92.70 million	82.13 million	Optionable
FTH Sensei Biotherapeutics	29	25.84 million	24.03 million	Not Optionable
IMMX Immix Biopharma	21	71.54 million	49.86 million	Optionable

AVXL, IMMX, FTH, and AVTX Headlines

Recent News About These Companies

Immix Biopharma (NASDAQ:IMMX) Stock Price Down 8.2% - Should You Sell?

September 23 at 2:59 PM | marketbeat.com

Mizuho Forecasts Strong Price Appreciation for Immix Biopharma (NASDAQ:IMMX) Stock

September 17, 2026 | americanbankingnews.com

Mizuho Issues Positive Forecast for Immix Biopharma (NASDAQ:IMMX) Stock Price

September 15, 2026 | marketbeat.com

Immix Biopharma Corporate Event Calendar | NASDAQ:IMMX

September 13, 2026 | benzinga.com

2,345,000 Shares in Immix Biopharma, Inc. $IMMX Bought by Opaleye Management Inc.

September 11, 2026 | marketbeat.com

Immix Biopharma (NASDAQ:IMMX) Stock Price Down 5.4% - What's Next?

September 8, 2026 | marketbeat.com

Wellington Management Group LLP Invests $15.19 Million in Immix Biopharma, Inc. $IMMX

September 8, 2026 | marketbeat.com

Bank of New York Mellon Corp Purchases New Shares in Immix Biopharma, Inc. $IMMX

September 8, 2026 | marketbeat.com

146,854 Shares in Immix Biopharma, Inc. $IMMX Purchased by The Manufacturers Life Insurance Company

September 4, 2026 | marketbeat.com

Velan Capital Investment Management LP Has $11.19 Million Stock Holdings in Immix Biopharma, Inc. $IMMX

September 2, 2026 | marketbeat.com

BlackRock Inc. Takes Position in Immix Biopharma, Inc. $IMMX

September 2, 2026 | marketbeat.com

Immix Biopharma, Inc. (NASDAQ:IMMX) Given Consensus Rating of "Moderate Buy" by Brokerages

August 31, 2026 | marketbeat.com

Jupiter Topco LLC Buys New Position in Immix Biopharma, Inc. $IMMX

August 27, 2026 | marketbeat.com

J. Goldman & Co LP Takes Position in Immix Biopharma, Inc. $IMMX

August 26, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX

August 13, 2026 | prnewswire.com

Analysts Are Bullish on These Healthcare Stocks: Immix Biopharma (IMMX), Ardelyx (ARDX)

August 12, 2026 | theglobeandmail.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX

August 11, 2026 | globenewswire.com

Regulatory and Data Risks Loom Over Immix Biopharma’s Clinical Programs and Valuation

August 10, 2026 | tipranks.com

IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law

August 7, 2026 | tmcnet.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX

August 6, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX

August 4, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL, IMMX, FTH, and AVTX Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

$15.72 +0.42 (+2.75%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$15.70 -0.02 (-0.13%)

As of 04:31 AM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Anavex Life Sciences NASDAQ:AVXL

$2.34 -0.01 (-0.43%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$2.35 +0.01 (+0.21%)

As of 05:14 AM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Sensei Biotherapeutics NASDAQ:FTH

$29.05 -2.50 (-7.92%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$29.06 +0.01 (+0.03%)

As of 09/24/2026 07:30 PM Eastern

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Immix Biopharma NASDAQ:IMMX

$11.70 -0.22 (-1.85%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$11.80 +0.10 (+0.85%)

As of 04:09 AM Eastern

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVXL, IMMX, FTH, and AVTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVXL, IMMX, FTH, and AVTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVXL, IMMX, FTH, and AVTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL, IMMX, FTH, and AVTX Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

Anavex Life Sciences NASDAQ:AVXL

Sensei Biotherapeutics NASDAQ:FTH

Immix Biopharma NASDAQ:IMMX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVXL, IMMX, FTH, and AVTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVXL, IMMX, FTH, and AVTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVXL, IMMX, FTH, and AVTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL, IMMX, FTH, and AVTX Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

Anavex Life Sciences NASDAQ:AVXL

Sensei Biotherapeutics NASDAQ:FTH

Immix Biopharma NASDAQ:IMMX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools